Fig. 3 | Scientific Reports

Fig. 3

From: Publisher Correction: Single-cell and bulk transcriptomics uncovers PRKD2-driven tumor stemness and progression in multiple myeloma

Fig. 3

Stemness indices, clinical stratification, survival impact. mRNAsi and EREG-mRNAsi across patient stratifications. Box-plots show log-scaled indices after propensity-score matching (PSM). Older patients (≥ 65 year) harbour higher stemness than younger cases. (A) Scores further increase from complete/partial remission (CR/PR) through newly diagnosed (NDMM) to relapsed/refractory (RRMM) myeloma, with lowest values in healthy donors (HD). (B) A step-wise rise is also evident across ISS stages I→III, whereas MGUS/SMM (“Other”) remain low. (C) Kruskal–Wallis tests: **P < 0.01; ***P < 0.001. (D,E) Kaplan–Meier curves dichotomised at the cohort median. High-stemness myeloma exhibits inferior 5-year overall survival (mRNAsi: 38% vs. 73%, log-rank P = 0.012; EREG-mRNAsi: 36% vs. 70%, P = 0.063).

Back to article page